{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:14:24Z","timestamp":1789802064834,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003669","name":"Korea Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejim.2020.10.022","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T08:59:22Z","timestamp":1607072362000},"page":"68-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3552-3560","authenticated-orcid":false,"given":"Hye Won","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Eun","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5363-2496","authenticated-orcid":false,"given":"Beom Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry Cheuk-Fung","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Kit","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Lai-Hung","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Lik-Yuen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3629-4624","authenticated-orcid":false,"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejim.2020.10.022_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ejim.2020.10.022_bib0002","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ejim.2020.10.022_bib0003","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3350\/cmh.2019.1002","article-title":"The Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B","volume":"25","year":"2019","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.ejim.2020.10.022_bib0004","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejim.2020.10.022_bib0005","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"European Association for the Study of the Liver (EASL). EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ejim.2020.10.022_bib0006","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejim.2020.10.022_bib0007","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"Kumar","year":"2008","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ejim.2020.10.022_bib0008","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.ejim.2020.10.022_bib0009","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jhep.2007.07.022","article-title":"The clinical significance of persistently normal ALT in chronic hepatitis B infection","volume":"47","author":"Lai","year":"2007","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ejim.2020.10.022_bib0010","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B","volume":"67","author":"Kim","year":"2018","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.ejim.2020.10.022_bib0011","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/infdis\/jix506","article-title":"Nucleos(t)ide analogue treatment for patients with hepatitis B virus (HBV) e antigen-positive chronic HBV genotype c infection: a nationwide, multicenter, retrospective study","volume":"216","author":"Chang","year":"2017","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.ejim.2020.10.022_bib0012","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/gutjnl-2017-315603","article-title":"Prognosis of immune-tolerant phase chronic hepatitis B","volume":"67","author":"Chu","year":"2018","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ejim.2020.10.022_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.ejim.2020.10.022_bib0014","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00535-020-01665-z","article-title":"Unresolved issues of immune tolerance in chronic hepatitis B","volume":"55","author":"Lee","year":"2020","journal-title":"J Gastroenterol"},{"issue":"3","key":"10.1016\/j.ejim.2020.10.022_bib0016","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3350\/cmh.2018.0090","article-title":"Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"10.1016\/j.ejim.2020.10.022_bib0017","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejim.2020.10.022_bib0018","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"European Association for the Study of Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.ejim.2020.10.022_bib0019","doi-asserted-by":"crossref","first-page":"e00036","DOI":"10.14309\/ctg.0000000000000036","article-title":"Prognosis of untreated minimally active chronic hepatitis B patients in comparison with virological responders by antivirals","volume":"10","author":"Lee","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"issue":"12","key":"10.1016\/j.ejim.2020.10.022_bib0020","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1136\/gutjnl-2013-306409","article-title":"Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease","volume":"63","author":"Cho","year":"2014","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.ejim.2020.10.022_bib0021","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3851\/IMP1982","article-title":"HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B","volume":"16","author":"Kim","year":"2011","journal-title":"Antivir Ther"},{"issue":"2","key":"10.1016\/j.ejim.2020.10.022_bib0022","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3350\/cmh.2017.0068","article-title":"Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend","volume":"24","author":"Wong","year":"2018","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.ejim.2020.10.022_bib0023","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1038\/s41598-019-39043-2","article-title":"Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals.","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejim.2020.10.022_bib0024","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/apt.15741","article-title":"Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase","volume":"52","author":"Lee","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.ejim.2020.10.022_bib0025","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/apt.15992","article-title":"Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B-authors' reply","volume":"52","author":"Lee","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ejim.2020.10.022_bib0026","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.21724","article-title":"Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase","volume":"46","author":"Hui","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejim.2020.10.022_bib0027","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2011.06.036","article-title":"Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma","volume":"141","author":"Chen","year":"2011","journal-title":"Gastroenterology"},{"issue":"7446","key":"10.1016\/j.ejim.2020.10.022_bib0028","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/bmj.38050.593634.63","article-title":"Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study","volume":"328","author":"Kim","year":"2004","journal-title":"BMJ"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520304088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520304088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:33:44Z","timestamp":1760607224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620520304088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":27,"alternative-id":["S0953620520304088"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2020.10.022","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2020.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}